A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
A phase 1/2 trial of BL-M02D1 in non-small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors is a phase 1/2 interventional study registered as NCT05949619 by Sichuan Baili Pharmaceutical Co., Ltd., with 14 participants enrolled, started 2023-09-04 and due to reach its primary completion in 2025-12. Interventions recorded: BL-M02D1.
Similar pages
not linked directly; found by shared links- TrialA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Shares SystImmune / Sichuan Biokin and the tag pipeline.
- TrialA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
Shares SystImmune / Sichuan Biokin and the tag pipeline.